UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Checkmate Pharmaceuticals, Inc.
(Name of Subject Company)
Checkmate Pharmaceuticals, Inc.
(Name of Persons Filing Statement)
COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE
(Title of Class of Securities)
162818108
(CUSIP Number of Class of Securities)
Katherine Eade
Checkmate Pharmaceuticals, Inc.
General Counsel
245 Main Street, 2nd Floor
Cambridge, MA 02142
(617) 682-3625
With copies to:
Stuart M. Cable, Esq.
Mitchell S. Bloom, Esq.
Robert Masella, Esq.
Andrew H. Goodman, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1000
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
| ☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 8.01 and 9.01 of the Current Report on Form 8-K filed by Checkmate Pharmaceuticals, Inc. on April 19, 2022 (including all exhibits attached thereto) is incorporated herein by reference.
